Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Thermal threshold testing (TTT) is a simple non-invasive approach for diagnosing diabetic neuropathy earlier. Conventionally the TTT is done in all four limbs and at least 6 trials are done to obtain the mean threshold, which is time consuming.

Aim: We propose to assess the validity and reliability of reduced number of trials of TTT in the lower limbs.

Materials And Methods: After obtaining ethics approval from the Institute Ethics Committee, 100 patients with type 2 Diabetes Mellitus of both gender between the ages of 35 to 65 years attending medicine OPD were recruited. Neuropathy assessment was done using Temperature threshold testing. At least 6 trials were performed for each site and the mean threshold obtained. The mean of 5 trials, 4 trials and 3 trials were noted for the comparison.

Results: On comparing hot tests of 3 trials with 6 trials had a sensitivity and specificity of 88.7% and 96.6 %. In cold threshold testing, 4 trials and 3 trials showed similar results of sensitivity of 77.8%, specificity of 98.8%. The measures of agreement between the hot trials 6 vs 5 had Kappa value of 0.953, 6vs 4 showed a Kappa value of 0.862 and 6 vs 3 showed Kappa value of 0.819.

Conclusion: Hot threshold tests of lower limb are more sensitive than cold thresholds. The 4 trial test is a reliable test and can be performed over 6 trial tests. When time is a factor, three trials are sufficient to diagnose small fibre neuropathy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412566PMC
http://dx.doi.org/10.4103/ijabmr.ijabmr_207_24DOI Listing

Publication Analysis

Top Keywords

threshold testing
16
trials trials
16
trials
12
thermal threshold
8
type diabetes
8
diabetes mellitus
8
testing trials
8
trials sensitivity
8
threshold
7
inter-trial variation
4

Similar Publications

Trachoma, caused by repeated ocular infection with Chlamydia trachomatis, remains a leading infectious cause of blindness globally, with significant implications for public health. The World Health Organization and partners aim to eliminate trachoma as a public health problem by 2030, targeting specific prevalence thresholds for trachomatous trichiasis (TT) and trachomatous inflammation-follicular (TF). Diagnosis is primarily clinical.

View Article and Find Full Text PDF

Objective: To evaluate speech perception deficit compensation and predict potential hearing aids (HA) effectiveness in patients with hearing loss (HL).

Design: The patients underwent pure-tone audiometry and various speech tests in quiet (evaluating the peripheral auditory system and cognitive compensation) and in noise (to quantify central compensation through auditory processing and cognitive abilities).

Study Sample: 513 HL patients aged 19-93 years, including 403 HA users.

View Article and Find Full Text PDF

The Quantiferon Gold Plus (QFT) test, a widely used interferon-γ release assay (IGRA), diagnoses latent tuberculosis infection (LTBI) with a positivity threshold of ≥0.35 IU/mL. Results near this cut-off can be challenging to interpret due to variability from immunological, pre-analytical, and technical factors, prompting recommendations for a borderline range to refine diagnosis and reduce overtreatment.

View Article and Find Full Text PDF

Criterion shifting reflects a complex interplay between cognitive strategies and external influences, yet individuals differ markedly in their tendency to adjust decision thresholds. While some readily adapt their criteria in response to task demands, others maintain more rigid thresholds, raising questions about the extent to which external pressures - such as social influence - can drive greater flexibility. Findings from social psychology reveal that social pressure can heavily impact individual decision-making, suggesting that such pressures may also impact individual criterion shifting tendencies.

View Article and Find Full Text PDF

Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.

View Article and Find Full Text PDF